BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2495020)

  • 21. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids.
    Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA
    Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
    Maheux R; Lemay A; Turcot-Lemay L
    Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid.
    Loong EP; Wong FW
    Fertil Steril; 1990 Sep; 54(3):530-1. PubMed ID: 2118862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
    West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
    Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical application of a gonadotropin releasing hormone analog (buserelin) in the treatment of uterine leiomyomas.
    Acar B; Posaci C
    Int J Gynaecol Obstet; 1992 May; 38(1):52-3. PubMed ID: 1348994
    [No Abstract]   [Full Text] [Related]  

  • 26. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women.
    Vollenhoven BJ; Pearce P; Herington AC; Healy DL
    Clin Endocrinol (Oxf); 1994 Apr; 40(4):537-44. PubMed ID: 8187322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uterine leiomyoma: treatment with LHRH agonist.
    Maheux R; Lemay A
    Prog Clin Biol Res; 1986; 225():297-311. PubMed ID: 3097669
    [No Abstract]   [Full Text] [Related]  

  • 28. Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin.
    Ueki M; Okamoto Y; Tsurunaga T; Seiki Y; Ueda M; Sugimoto O
    J Obstet Gynaecol (Tokyo 1995); 1995 Feb; 21(1):1-7. PubMed ID: 8591104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
    Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
    Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.
    Letterie GS; Coddington CC; Winkel CA; Shawker TH; Loriaux DL; Collins RL
    Fertil Steril; 1989 Jun; 51(6):951-6. PubMed ID: 2498132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of goserelin-depot in the clinical management of uterine fibroids.
    Cagnacci A; Paoletti AM; Soldani R; Angiolucci M; Arangino S; Falqui A; Melis GB
    Clin Exp Obstet Gynecol; 1994; 21(4):263-5. PubMed ID: 7994879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Medical treatment of uterine leiomyomatosis with an agonist of pituitary gonadotropins (GnRH). Presentation of a case].
    Bustos HH; López Garcia R; Sánchez V; Contreras J; Ayala Ruiz A
    Ginecol Obstet Mex; 1990 Sep; 58():260-4. PubMed ID: 2125961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas.
    Maheux R; Lemay A; Merat P
    Fertil Steril; 1987 Feb; 47(2):229-33. PubMed ID: 3102282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The binding of steroids to myometrium and leiomyomata (fibroids) in women treated with the gonadotrophin-releasing hormone agonist Zoladex (ICI 118630).
    Lumsden MA; West CP; Hawkins RA; Bramley TA; Rumgay L; Baird DT
    J Endocrinol; 1989 May; 121(2):389-96. PubMed ID: 2526844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma.
    Ito M; Sakoda Y; Okamura H
    Endocrinol Jpn; 1990 Dec; 37(6):907-13. PubMed ID: 1966283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pelvic pain complicating LHRH analogue treatment of fibroids.
    Chipato T; Healy DL; Vollenhoven B; Buckler HM
    Aust N Z J Obstet Gynaecol; 1991 Nov; 31(4):383-4. PubMed ID: 1799362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
    Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging.
    Williams IA; Shaw RW
    Eur J Obstet Gynecol Reprod Biol; 1990; 34(1-2):111-7. PubMed ID: 2137421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.